FNIP2 Inhibitors
FNIP2 inhibitors are a category of compounds specifically designed to target and modulate the activity of the FNIP2 protein, which is involved in cellular processes including energy metabolism, autophagy, and possibly the modulation of immune responses. The development of these inhibitors is a complex process that starts with a comprehensive understanding of the protein's structure, function, and its role within cellular signaling pathways. High-throughput screening (HTS) techniques are employed to identify compounds that exhibit inhibitory effects against FNIP2. This involves the assessment of thousands of chemical entities to determine their ability to bind to and inhibit the activity of FNIP2. Once potential inhibitors are identified, structure-activity relationship (SAR) studies are undertaken to optimize these compounds. SAR analysis involves modifying the chemical structure of these compounds to enhance their potency, specificity, and pharmacokinetic properties, ensuring that they effectively target FNIP2 without undesirable off-target effects.
The refinement of FNIP2 inhibitors is further guided by advanced molecular and structural biology techniques. X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy are pivotal in providing detailed insights into the three-dimensional structure of the FNIP2-inhibitor complex. These techniques reveal the precise interactions between the inhibitor and specific amino acids in the protein, allowing for the rational design of more effective inhibitors. Additionally, in vitro assays are conducted to assess the biological activity of these compounds, confirming their ability to inhibit FNIP2 in a cellular context. These assays help in understanding the impact of FNIP2 inhibition on cellular processes and validate the potential of these inhibitors to modulate FNIP2 activity effectively. Through iterative cycles of design, synthesis, and testing, FNIP2 inhibitors are optimized for maximum efficacy and selectivity. This rigorous approach ensures the development of FNIP2 inhibitors that can precisely target and modulate the function of this protein, providing valuable tools for the study of FNIP2's role in cellular physiology.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is a macrolide antibiotic that can inhibit the mechanistic target of rapamycin (mTOR) signaling pathway. FNIP2 is known to interact with mTOR and regulate its activity. By inhibiting mTOR with rapamycin, it can potentially disrupt the interaction between FNIP2 and mTOR, leading to altered signaling and function of FNIP2. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a selective inhibitor of phosphoinositide 3-kinase (PI3K), a key enzyme in the PI3K/AKT signaling pathway. FNIP2 has been shown to interact with AKT and modulate its activity. By inhibiting PI3K with LY 294002, it can potentially disrupt the interaction between FNIP2 and AKT, affecting the downstream signaling and function of FNIP2. | ||||||
17-AAG | 75747-14-7 | sc-200641 sc-200641A | 1 mg 5 mg | $67.00 $156.00 | 16 | |
17-AAG is a selective inhibitor of heat shock protein 90 (HSP90), a chaperone protein involved in the folding and stabilization of client proteins. FNIP2 has been reported to interact with HSP90. By inhibiting HSP90 with 17-AAG, it can potentially disrupt the interaction between FNIP2 and HSP90, leading to altered stability and function of FNIP2. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 [Z-Leu- Leu-Leu-CHO] is a reversible inhibitor of the proteasome, a cellular complex responsible for protein degradation. By inhibiting the proteasome, MG-132 [Z-Leu- Leu-Leu-CHO] can potentially increase the stability and accumulation of FNIP2 protein, leading to enhanced expression and function. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a potent inhibitor of histone deacetylases (HDACs), enzymes that remove acetyl groups from histone proteins, affecting gene expression. HDAC inhibitors can modulate the expression of genes, including FNIP2, by increasing histone acetylation and promoting a more open chromatin structure, allowing for increased transcriptional activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can disrupt protein degradation. By inhibiting the proteasome, bortezomib can potentially increase the stability and accumulation of FNIP2 protein, leading to enhanced expression and function. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1 is a selective inhibitor of bromodomain and extra-terminal (BET) proteins, which are involved in the regulation of gene expression. By inhibiting BET proteins, JQ1 can potentially modulate the expression of genes, including FNIP2, by disrupting their interaction with chromatin. | ||||||
Metformin | 657-24-9 | sc-507370 | 10 mg | $79.00 | 2 | |
Metformin is an antidiabetic compound that activates AMP-activated protein kinase (AMPK), a cellular energy sensor. FNIP2 has been reported to interact with AMPK and regulate its activity. By activating AMPK with metformin, it can potentially modulate the interaction between FNIP2 and AMPK, leading to altered signaling and function of FNIP2. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Suberoylanilide Hydroxamic Acid is a histone deacetylase (HDAC) inhibitor that can increase histone acetylation and promote a more open chromatin structure. By inhibiting HDACs, Suberoylanilide Hydroxamic Acid can potentially influence the expression and function of genes, including FNIP2, by modulating histone acetylation. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $245.00 | 7 | |
Torin 1 is a selective inhibitor of the mechanistic target of rapamycin complex 1 (mTORC1), a key regulator of cellular growth and metabolism. FNIP2 is known to interact with mTOR and regulate its activity. By inhibiting mTORC1 with Torin 1, it can potentially disrupt the interaction between FNIP2 and mTOR, leading to altered signaling and function of FNIP2. | ||||||